- Home
- EVAX vs AIMD Comparison
EVAX vs AIMD Comparison
Compare EVAX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- AIMD
- Stock Information
- Founded
- EVAX 2008
- AIMD 1984
- Country
- EVAX Denmark
- AIMD United States
- Employees
- EVAX N/A
- AIMD N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- AIMD Health Care
- Exchange
- EVAX Nasdaq
- AIMD Nasdaq
- Market Cap
- EVAX 8.7M
- AIMD 8.2M
- IPO Year
- EVAX 2021
- AIMD N/A
- Fundamental
- Price
- EVAX $2.41
- AIMD $0.87
- Analyst Decision
- EVAX Strong Buy
- AIMD
- Analyst Count
- EVAX 2
- AIMD 0
- Target Price
- EVAX $11.00
- AIMD N/A
- AVG Volume (30 Days)
- EVAX 250.1K
- AIMD 1.4M
- Earning Date
- EVAX 10-31-2024
- AIMD 03-07-2025
- Dividend Yield
- EVAX N/A
- AIMD N/A
- EPS Growth
- EVAX N/A
- AIMD N/A
- EPS
- EVAX N/A
- AIMD N/A
- Revenue
- EVAX $3,295,000.00
- AIMD $40,633.00
- Revenue This Year
- EVAX $4,845.21
- AIMD N/A
- Revenue Next Year
- EVAX $30.30
- AIMD N/A
- P/E Ratio
- EVAX N/A
- AIMD N/A
- Revenue Growth
- EVAX N/A
- AIMD N/A
- 52 Week Low
- EVAX $2.38
- AIMD $0.40
- 52 Week High
- EVAX $68.05
- AIMD $3.10
- Technical
- Relative Strength Index (RSI)
- EVAX 23.50
- AIMD 64.26
- Support Level
- EVAX $2.38
- AIMD $0.55
- Resistance Level
- EVAX $3.90
- AIMD $0.77
- Average True Range (ATR)
- EVAX 0.51
- AIMD 0.14
- MACD
- EVAX -0.05
- AIMD 0.01
- Stochastic Oscillator
- EVAX 2.72
- AIMD 64.77
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.